Key facts, as of
As of October 8, 2026, IDEXX Laboratories (IDXX) trades at $506.67, down 19.2% over the past year. Its 52-week range runs from $500.61 to $769.98; the price is 34.2% below that high. It is 34.2% below its all-time high of $769.98, reached in November 2025. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +363.2%, against +312.9% for the S&P 500 (SPY). It sits 13.4% below its 200-day average of $585.27, the usual sign of a long-term downtrend. Its 30-day volatility is 20.2% annualized, which we rate medium risk. It has a trailing P/E of 35.6.
Cite: Portfolio Terminal, "IDEXX Laboratories (IDXX) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/idxx
Where it trades today
trading 2% of the way up its 52-week range
How the price has moved
How far it is from its record
IDEXX Laboratories (IDXX) is 34.2% below its all-time high of $769.98, reached in November 2025. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +363.2%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- IDXX trades at 35.6x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- IDXX carries a beta of 1.55, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- IDXX is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in IDXX.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for IDXX come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for IDXX. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What IDEXX Laboratories does
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services,…
What analysts expect
IDXX carries a buy consensus from 12 analysts, with an average price target of $701.33 versus $506.67 today (+38.4%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
IDXX generated $4.55B in trailing revenue (9.7% year over year), with a 25.0% net margin, and $909.37M of free cash flow, against $899.15M of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $4.30B | $2.66B | $1.36B | $1.06B | $13.17 | $1.04B |
| 2024 | $3.90B | $2.38B | $1.13B | $887.87M | $10.77 | $798.08M |
| 2023 | $3.66B | $2.19B | $1.10B | $845.04M | $10.17 | $772.88M |
| 2022 | $3.37B | $2.00B | $898.76M | $679.09M | $8.12 | $384.15M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
IDXX is in 8 of the 30 ETFs we track. It weighs most in XLV: 0.65% of the fund, holding #35 of 62.
Famous investors who hold it
IDXX is in the latest 13F of 1 of the 15 famous investors we follow. Terry Smith (Fundsmith) holds the most of it: 3.93% of the portfolio, position #15 of 41, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
IDXX beside the healthcare names it is usually measured against.
What the chart is saying
In a downtrend, below both moving averages.
downtrend- Price is 6.4% below its 50-day average and 13.4% below its 200-day.
- RSI at 40 is neither stretched nor washed out.
- The nearest ceiling is $520.96 (+2.8%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is IDXX a good investment in 2026?
IDEXX Laboratories trades at a P/E ratio of 35.6, with medium volatility (20.2% annualized). The stock is in a consolidation phase.
What is the risk level of IDXX?
Based on 30-day volatility of 20.2%, IDXX has MEDIUM risk. Beta of 1.55 indicates higher sensitivity to market movements than average.
Does IDXX pay dividends?
IDEXX Laboratories currently does not pay a regular dividend.
How far is IDXX from its all-time high?
IDEXX Laboratories is 34.2% below its all-time high of $769.98, reached in November 2025. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +363.2%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold IDXX?
8 of the 30 popular ETFs we track hold IDEXX Laboratories. The largest weights: XLV (0.65%), QQQM (0.17%), QQQ (0.17%), VUG (0.14%) and VOO (0.07%). Measured on each issuer's full holdings file, dated August 31 to October 1, 2026.
How much of VOO is IDXX?
0.07%, as of August 31, 2026: IDXX is holding #248 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.66 in IDEXX Laboratories.
Which famous investors own IDXX?
Terry Smith (3.93% of Fundsmith's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for IDXX?
The average analyst price target for IDEXX Laboratories (IDXX) is $701.33 based on 12 analyst estimates, about 38.4% above the current price of $506.67. The published range runs from $470.00 to $805.00.
How much revenue does IDXX generate?
IDEXX Laboratories reported $4.55B in trailing twelve-month revenue. Revenue growth is running at 9.7% year over year. Net margin sits at 25.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare IDXX with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.